Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort study.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in China in December 2019 and rapidly spread worldwide. Patient characteristics are described in Table S1: 21 (38-8%) had severe COVID-19, including 13 transferred to ICU and eight deceased from COVID-19 outside of ICU (Figure S1). GLO:1XW/01mar21:bjh17260-fig-0001.jpg PHOTO (COLOR): 1 Survival curve after COVID-19 diagnosis. gl Haematological characteristics did not vary between patients with severe or non-severe forms of COVID-19 (Table S1). Patient collection was prospective, so no case should have been missed in the participating centres, but we cannot exclude an underestimation of the true incidence of COVID-19 among alloHSCT recipients if pauci-symptomatic patients did not report to their transplant centre. [Extracted from the article]